March 18, 2025



C4U Corporation

Japan Patent Office Decides to Maintain CRISPR-Cas3 Basic Patent (Patent No. 7301332)

C4U Corporation ("C4U") has been granted an exclusive license, including sublicense rights, from Osaka University for inventions related to CRISPR-Cas3, a novel genome editing technology, with the aim of commercializing the technology.

Among the inventions related to CRISPR-Cas3 technology, the patent for the invention, "METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD," was issued by the Japan Patent Office (Patent No. 6480647), and its divisional applications were matured into Patents Nos. 7301332 and 7430358. C4U had announced that the claims and the scope of these patents had become broader than the basic patent for CRISPR-Cas3 system.

Subsequently, a third party filed an opposition to Patent No.7301332 in January 2024, and C4U received a notice of reasons for revocation of this patent from the Board of Appeal in June 2024. Regarding this issue, C4U submitted written opinions as well as the revision of claims to the Board After the Review of the case the Board of Appeal approved C4U's opinions and decided to maintain this patent. Although the scope of the patent was partially narrowed from its original version, the same scope is still pending in the divisional application.

The invention has also been patented outside Japan in Eurasia (Patent No. 040859), Korea (Patent No. 10-2541398), the United States (Patent No. 11807869), China (Patent No. 110770342), Europe (Patent No. 3636753), Australia (Patent No. 2018279457), Mexico (Patent No. 415175) and India (Patent No. 548919).

C4U will further strengthen its intellectual property portfolio for CRISPR-Cas3 technology worldwide to contribute to the creation of a sustainable society by applying the technology to a wide range of industries, including medicine.

About C4U Corporation

C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by Osaka University for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape. https://www.crispr4u.jp/en/

Contact Information

Address : Yamadaoka 2-8, Suita, Osaka 565-0871, Japan E-mail : <u>info@crispr4u.com</u>